 WEST LAFAYETTE, Ind., Sept. 27, 2021 GLOBE NEWSWIRE -- Inotiv, Inc. NASDAQ:NOTV the Company, We, Our or Inotiv, a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the closing of its offering of 140,000,000 aggregate principal amount of 3.25 convertible senior notes due 2027 the notes, including 15,000,000 of additional notes, in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended the Securities Act. The Companys obligations under the notes are guaranteed by BAS Evansville, Inc., a wholly owned subsidiary of the Company. 